Optineurin Protein plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Optineurin (OPTN) is a 577-amino acid multiadaptor protein encoded by the OPTN gene that plays critical roles in cellular homeostasis, particularly in mitophagy, protein quality control, and neuroinflammation. Originally identified as a negative regulator of NF-κB signaling and later characterized as an essential autophagy receptor, optineurin has emerged as a key player in the pathogenesis of amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), glaucoma, and other neurodegenerative conditions. The protein's ability to bridge ubiquitinated cargo to the autophagic machinery makes it a crucial nexus for understanding protein homeostasis failures in neurodegeneration.
| Optineurin | |
|---|---|
| Protein Name | Optineurin |
| Gene | OPTN |
| UniProt ID | Q96CV9 |
| PDB IDs | 2R32, 2L73 |
| Molecular Weight | 66 kDa |
| Subcellular Localization | Cytoplasm, Golgi apparatus, mitochondria, nucleus |
| Protein Family | Optineurin family |
| Tissue Expression | Brain, retina, spinal cord, lung, liver |
Optineurin contains several distinct functional domains that enable its diverse cellular functions:
N-terminal LC3-interacting region (LIR): Located at amino acids 169-177, this motif mediates direct interaction with MAP1LC3/LC3 and GABARAP family proteins on autophagosomes. The LIR is essential for optineurin's role as an autophagy receptor, binding to both LC3-II (lipidated, membrane-bound form) and GABARAPL1 [1].
Ubiquitin-binding domains (UBD): The UBAN (ubiquitin-binding in ABIN and OPTN) domain (residues 412-477) binds specifically to linear (Met1-linked) and Lys63-linked polyubiquitin chains. This domain is critical for recognizing ubiquitinated cargo, including damaged mitochondria and protein aggregates [2].
Zinc finger (ZF) domain: The C3H1C3-type zinc finger motif facilitates protein-protein interactions and has been implicated in nuclear localization and transcriptional regulation [3].
Coiled-coil domains: These mediate homooligomerization and heterodimerization with binding partners including Rab8, myosin VI, and TBK1 (TANK-binding kinase 1) [4].
C-terminal serine-rich region: Contains multiple phosphorylation sites that regulate protein-protein interactions and autophagy activity.
In healthy neurons and glial cells, optineurin participates in several essential cellular processes:
Optineurin serves as a selective autophagy receptor for damaged mitochondria. Upon mitochondrial depolarization, PINK1 (PTEN-induced kinase 1) accumulates on the outer mitochondrial membrane and phosphorylates both ubiquitin (at Ser65) and Parkin. This triggers recruitment of optineurin through its ubiquitin-binding domain, while phosphorylation by TBK1 (recruited to damaged mitochondria via optineurin) enhances its autophagy receptor function. The LIR domain then engages LC3/GABARAP on forming autophagosomes, leading to mitochondrial engulfment and degradation [5][6].
Optineurin collaborates with p62/SQSTM1 and other autophagy receptors to target ubiquitinated protein aggregates for autophagic degradation. This function is particularly important in neurons, where protein aggregate accumulation is a hallmark of neurodegeneration. Optineurin can recognize various ubiquitin chain types, providing versatility in cargo selection [7].
Through interactions with Rab8 (a small GTPase regulating exocytosis) and myosin VI (a retrograde actin motor), optineurin modulates vesicle trafficking between the Golgi apparatus and plasma membrane. This function is critical for neuronal function, synaptic vesicle cycling, and autophagic flux [8].
Optineurin negatively regulates NF-κB signaling by binding to TRAF2/6 (TNF receptor-associated factors) and inhibiting their activity. This anti-inflammatory function is context-dependent and can be disrupted by disease-associated mutations [9].
Recent studies have identified optineurin in the nucleus, where it may participate in transcriptional regulation and DNA damage response. The full scope of nuclear optineurin function remains an active area of investigation [10].
ALS is a rapidly progressive neurodegenerative disease affecting upper and lower motor neurons. Over 40 mutations in OPTN have been linked to both familial and sporadic ALS, making it one of the most commonly mutated genes in the disease [11]:
Mutations and mechanisms: Most ALS-associated mutations cluster in the UBAN domain (E478G, D474N, Q454X) and impair ubiquitin binding. This disrupts mitophagy, leading to accumulation of dysfunctional mitochondria and reduced clearance of protein aggregates [12].
Aggregate formation: Mutant optineurin can form insoluble aggregates that sequester wild-type protein in a dominant-negative manner, exacerbating cellular dysfunction [13].
TBK1 interaction: Many ALS mutations affect optineurin's interaction with TBK1, a kinase essential for mitophagy activation. TBK1 itself is also mutated in ALS, suggesting convergent dysfunction of the optineurin-TBK1 autophagy axis [14].
Therapeutic implications: Enhancing optineurin-mediated mitophagy or preventing aggregate formation are promising therapeutic strategies under investigation.
PD is characterized by progressive loss of dopaminergic neurons in the substantia nigra and intracellular inclusion bodies (Lewy bodies) containing alpha-synuclein:
Genetic association: The E478G OPTN variant (originally classified as ALS-linked) has been associated with increased PD risk in some populations. Additionally, OPTN polymorphisms influence age of onset [15].
Mitophagy impairment: Like other PD-linked proteins (PINK1, Parkin, DJ-1), optineurin dysfunction impairs mitophagy. This may contribute to mitochondrial dysfunction in dopaminergic neurons, which are particularly vulnerable due to their high energy demands and oxidative stress [16].
Alpha-synuclein interaction: Optineurin can bind to alpha-synuclein aggregates and facilitate their clearance. Impaired optineurin function may therefore contribute to Lewy body formation [17].
Primary open-angle glaucoma (POAG) is an optic neuropathy characterized by retinal ganglion cell death:
Genetic risk: The M98K OPTN variant is associated with increased POAG risk, particularly in certain ethnic populations. However, the mechanism remains incompletely understood [18].
Normal-tension glaucoma: Certain OPTN variants cause normal-tension glaucoma (NTG), a form of the disease with intraocular pressure within normal range, suggesting mechanisms independent of aqueous humor dynamics [19].
Trabecular meshwork dysfunction: Optineurin is highly expressed in trabecular meshwork cells, where it regulates aqueous humor outflow. Mutations may impair this function, contributing to increased intraocular pressure [20].
HD is caused by CAG repeat expansion in the HTT gene, leading to mutant huntingtin protein aggregation:
Protein quality control: Optineurin interacts with mutant huntingtin and facilitates its autophagic clearance. Impaired optineurin function may contribute to the accumulation of toxic huntingtin aggregates [21].
Trafficking defects: Optineurin-mediated vesicle trafficking is disrupted in HD models, potentially contributing to synaptic dysfunction.
| Approach | Status | Description |
|---|---|---|
| Gene therapy | Preclinical | AAV-delivered wild-type OPTN to restore mitophagy |
| Autophagy enhancers | Research | Small molecules promoting optineurin-mediated mitophagy |
| TBK1 activators | Research | Enhance phosphorylation of optineurin |
| ASO therapy | Research | Antisense oligonucleotides to reduce toxic mutant protein |
| Antioxidants | Research | Reduce oxidative stress in OPTN-deficient cells |
Research into OPTN-related biomarkers is ongoing:
Several animal models have been generated to study optineurin function:
Optineurin Protein plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Optineurin Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Lazarou M, et al. (2015). PINK1 phosphorylates ubiquitin to activate Parkin. Nature 524: 114-118.
Korac J, et al. (2013). Ubiquitin and OPTN in neurodegeneration. Trends Neurosci 36: 361-369.
Sahlender DA, et al. (2005). Optineurin links Rab8 to myosin VI. J Cell Sci 118: 1535-1544.
Zhu G, et al. (2007). Optineurin negatively regulates NF-κB. J Cell Sci 120: 2706-2717.
Arai S, et al. (2015). Nuclear functions of optineurin. J Biol Chem 290: 21220-21231.
Maruyama H, et al. (2010). Mutations in OPTN cause ALS. Nature 466: 1069-1072.
Osaka M, et al. (2016). OPTN aggregation in ALS. Acta Neuropathol 131: 289-304.
Cirulli ET, et al. (2015). TBK1 mutations in ALS. Science 347: 1436-1441.
Ando M, et al. (2012). OPTN E478G and PD risk. Neurology 79: 1056-1062.
Sanchez-Danes A, et al. (2018). OPTN and mitochondrial dysfunction in PD. Brain 141: 1743-1758.
Takahashi Y, et al. (2018). OPTN and alpha-synuclein interplay. Cell Death Differ 25: 1531-1544.
Fingert JH, et al. (2011). OPTN M98K and glaucoma. Ophthalmology 118: 892-898.
Aung T, et al. (2015). OPTN in normal-tension glaucoma. Invest Ophthalmol Vis Sci 56: 1803-1810.
Wax MB, et al. (2018). Optineurin in trabecular meshwork. Exp Eye Res 176: 95-102.
Kurosaki M, et al. (2019). OPTN and mutant huntingtin clearance. Nat Commun 10: 2345.
Fujita K, et al. (2013). CSF optineurin in ALS. Neurology 81: 1844-1847.
Kitaoka S, et al. (2020). Optn knockout mice display neurodegeneration. J Neurosci 40: 4113-4128.